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Abstract
Bipolar disorder (BPD) and major depressive disorder (MDD) are primary major mood disorders. Recent studies suggest
that they share certain psychopathological features and common risk genes, but unraveling the full genetic
architecture underlying the risk of major mood disorders remains an important scientiﬁc task. The public genome-
wide association study (GWAS) data sets offer the opportunity to examine this topic by utilizing large amounts of
combined genetic data, which should ultimately allow a better understanding of the onset and development of these
illnesses. Genome-wide meta-analysis was performed by combining two GWAS data sets on BPD and MDD (19,637
cases and 18,083 controls), followed by replication analyses for the loci of interest in independent 12,364 cases and
76,633 controls from additional samples that were not included in the two GWAS data sets. The single-nucleotide
polymorphism (SNP) rs10791889 at 11q13.2 was signiﬁcant in both discovery and replication samples. When
combining all samples, this SNP and multiple other SNPs at 2q11.2 (rs717454), 8q21.3 (rs10103191), and 11q13.2
(rs2167457) exhibited genome-wide signiﬁcant association with major mood disorders. The SNPs in 2q11.2 and 8q21.3
were novel risk SNPs that were not previously reported, and SNPs at 11q13.2 were in high LD with potential BPD risk
SNPs implicated in a previous GWAS. The genome-wide signiﬁcant loci at 2q11.2 and 11q13.2 exhibited strong effects
on the mRNA expression of certain nearby genes in cerebellum. In conclusion, we have identiﬁed several novel loci
associated with major mood disorders, adding further support for shared genetic risk between BPD and MDD. Our
study highlights the necessity and importance of mining public data sets to explore risk genes for complex diseases
such as mood disorders.
Introduction
Major mood disorders, including bipolar disorder (BPD)
and major depressive disorder (MDD), are leading causes
of disability worldwide that account for a substantial
proportion of productivity loss, life quality impairment,
poor physical health, and deaths by suicide1,2. Earlier
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family and twin studies indicated a pivotal role of genetic
factors in the etiology of mood disorders3–6; however, the
speciﬁc modes of inheritance have been found to be
complex and polygenic7–10. In brief, while BPD and MDD
differ from each other in age of onset, clinical presenta-
tion, and treatment response11, they still share several
speciﬁc clinical features such as the presence of depressive
episodes, mood instability and impaired cognition.
Moreover, meta-analyses of family studies have found
elevated rates of BPD in ﬁrst-degree relatives of MDD
patients and vice versa12. Taken together, there are likely
shared genetic components underlying the pathogenesis
of BPD and MDD. However, molecular genetic studies
have provided limited evidence for this contention so far
and only a handful of common risk genes for major mood
disorders have been reported to date13,14. For example, in
a previous study, McMahon et al.15 performed a genome-
wide association study (GWAS) in a major mood disorder
sample of 13,600 individuals, and found a genomic locus
at 3p21.1 showing genome-wide signiﬁcant association,
though the risk SNP was latter shown to have stronger
association with BPD than with MDD16,17. Therefore,
understanding the genetic mechanism and pathogenic
basis of major mood disorders still remains an important
task.
To date, there have been several GWAS conducted in
BPD or MDD samples9,18–38. Though the current GWAS
of mood disorders have identiﬁed fewer genome-wide
signiﬁcant genes than expected, their genome-wide sta-
tistical results have been (completely or partially) released
publicly and these are valuable resources for further
larger-scale GWAS meta-analysis. This systematic utili-
zation of these public GWAS resources offers a great
opportunity to perform genome-wide screens of the
underlying shared genetic factors and will provide valu-
able information that will beneﬁt other studies of major
mood disorders. Therefore, we conducted a genome-wide
meta-analysis of GWAS statistics utilizing large samples
of individuals diagnosed with BPD or MDD and control
subjects, followed by replications of suggestive associa-
tions (p< 1.0× 10–6) in multiple independent samples
from diverse populations (including a total of 32,001 cases
and 94,716 controls). This study highlights that there are
undiscovered “treasures” underlying the current mood
disorder GWAS data sets, and illustrates an example of
utilizing available public resources to further dissect the
genetic basis of mood disorders.
Methods
Research strategy and experimental design
We performed a meta-analysis of two GWAS data sets
in a total of 19,637 cases and 18,083 controls of European
ancestry. We then evaluated the SNPs with suggestive
genome-wide associations (p< 1.0× 10–6) in additional
12,364 cases and 76,633 controls from various ethnic
groups (Supplementary Table S1). All the protocols and
methods used in this study were approved by the insti-
tutional review board of the Kunming Institute of Zool-
ogy, Chinese Academy of Sciences.
GWAS data sets meta-analysis
In the discovery stage, we performed a meta-analysis
using summary statistics from a BPD GWAS and a non-
overlapping MDD GWAS9,18. The BPD GWAS sample9
comprised 10,410 cases and 10,700 controls that partially
overlapped with the Psychiatric Genomics Consortium
(PGC1) BPD GWAS sample20. Clinical information
regarding lifetime history of psychiatric illnesses was col-
lected via standardized semi-structured interviews, and
lifetime diagnoses were based on operationalized criteria.
All cases had experienced pathological episodes of elevated
mood (mania or hypomania) and depression and met the
criteria for BPD within the primary study classiﬁcation
system. Controls were individuals without BPD selected
from the same ethnic groups within the same geographical
area. For the MDD analyses, we collected data of 9227
patients and 7383 controls from the PGC1 MDD GWAS
sample18. The cases were deﬁned by having lifetime
diagnoses of MDD according to DSM-IV criteria by
trained interviewers, or based on clinician-administered
DSM-IV checklists using structured diagnostic instru-
ments. For most of these participants, cases were obtained
from clinical sources, and controls were randomly selected
from the population. Detailed description of the samples,
data quality, genomic controls, and statistical analyses can
be found in the original GWAS reports9,18.
Illumina OmniExpress, Omni2.5, HumanHap610K,
HumanCNV360-Duo or Affymetrix 6.0 were used for the
genotyping9,18. In both GWAS, strict quality control
metrics were applied to ensure the quality of the results.
Samples with poor call rates, gender discordance, and/or
abnormal heterozygosity as well as those of non-European
ancestry were excluded. SNPs with a call rate <95% or
Hardy–Weinberg Equilibrium (HWE) p-value <1× 10–6
were removed. Each GWAS was imputed separately using
IMPUTE2, and SNPs which were poorly imputed (INFO
score <0.3) or had minor allele frequency <5% were
excluded. There were ~1.3 million SNPs left for the cur-
rent meta-analysis. In each GWAS, the associations of
clinical diagnosis with SNP dosage was tested using
logistic regression under an additive model, and covari-
ates such as sample grouping and principal components
reﬂecting the ancestry were taken into consideration.
Meta-analyses of GWAS summary statistics were con-
ducted using an inverse variance method under an
appropriate effect model according to the test of hetero-
geneity. Manhattan, quantile–quantile (QQ) and regional
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plots were made using R (qqman package)39 and Locus-
Zoom40, respectively.
Replication and technical validation
Replication analyses of the candidate loci were under-
taken in two stages in a total of 12,364 cases and 76,633
controls from nine additional samples. The purpose of
stage 1 replication was to narrow down the list of candi-
date SNPs. Since we believe that true genetic risk factors
for general populations should show consistent signiﬁcant
associations with mood disorders, we performed this
initial replication using the results from either publicly
released data sets or from our own samples. After the
initial replication, the candidate SNPs underwent the
stage 2 replication, in which we collected large samples
from international collaborators, and the associations
survived stage 1 replication were further tested to conﬁrm
their roles in mood disorders. Detailed information of
individual samples—including diagnostic assessment,
genotyping and quality control—are shown in the Sup-
plemental Data and Supplementary Table S1. The sub-
jects of the replication samples were recruited under
relevant ethical and legal guidelines within their respec-
tive areas, and all subjects provided written informed
consent prior to participation.
There were 40 SNPs reaching the signiﬁcance threshold
of p< 1.0× 10–6 in the discovery GWAS meta-analysis
and were taken forward for validation in the Replication
sample I, which included a BPD-type I sample from
Romania (Romanian, 451 cases and 318 controls)41 and a
MDD sample from the CONVERGE consortium (Chi-
nese, 5303 cases and 5337 controls)21. These two samples
were mainly comprising more homogeneous patients that
have been discussed previously21,41, ensuring that we can
identify true signals using these samples. In addition, we
believe that using trans-ethnic sample (CONVERGE)
helps to screen for authentic risk signals across popula-
tions. The 40 SNPs were ﬁrst analyzed in each of these
two samples and in the total Replication sample I, and
then meta-analyzed in the total Replication sample I
combining the discovery GWAS under an inverse var-
iance weighted ﬁxed-effect model. p-Values for hetero-
geneity were calculated using the Cochran’s Q-test. Five
SNPs showing p-value lower than 5.0× 10–8 in the
combined samples were considered genome-wide sig-
niﬁcant, and were then subject to analyses in Replication
sample II to further validate the associations.
The data sources of Replication sample II were mainly
international collaborators, and most of the data sets have
been used in previous large-scale studies to identify risk
loci for mood disorders13,14. In brief, the Replication
sample II were comprised of 6610 cases and 70,978 con-
trols in total from Australia (330 BPD cases and 1811
controls)14, Germany (181 BPD cases and 527 controls)13,
Japan (2964 BPD cases and 61,887 controls)22, GAIN
African American (362 BPD cases and 671 controls)34, the
Netherlands (389 MDD cases and 2056 controls)38,
Switzerland (the PsyCoLaus cohort of 1301 MDD cases
and 1689 controls)13, and China (1083 MDD cases and
2337 controls). Association analyses for the risk SNPs
were conducted ﬁrst in each of the above samples alone
using logistic regression, and then meta-analyzed in the
pooled Replication sample II to examine the overall
associations. All assays were performed blind to diagnosis
and genotype.
Healthy subjects for expression quantitative trait loci
analysis
To identify the impact of risk SNPs on mRNA expres-
sion, we utilized two well-characterized gene expression
databases to explore the gene expression regulation in the
human tissues, providing valuable resources for functional
follow-up studies for certain disease-associated variants.
We carried out both discovery and replication analyses
respectively using each database. We ﬁrst used the GTEx
(Genotype-Tissue Expression project)42 data set for the
discovery analyses. GTEx contains both genetic variation
and RNA-seq gene expression data from a diverse set of
human tissues. The dorsolateral prefrontal cortex
(DLPFC), hippocampus and cerebellum tissues have been
highlighted in the pathogenesis of major mood disorders,
we therefore retrieved data of tissues from these brain
regions from GTEx for the expression quantitative trait
loci (eQTL) analyses. Genes within 200 kb away from each
risk SNP were analyzed for eQTL effects of that particular
SNP, and Bonferroni correction was applied according to
the number of included genes and brain tissues. To
replicate the discovery in an independent sample, we
conducted the replication analyses using data from the
Braineac43, the database containing genetic information
and whole transcriptome microarray expression infor-
mation from postmortem brain tissues of 134 normal
Caucasians. More detailed information regarding sample
collection, processing and analyses can be found in the
original studies42,43.
Results
Discovery GWAS meta-analyses and replication sample I
analyses
We ﬁrst conducted a meta-analysis of a BPD GWAS
and a MDD GWAS comprising of 19,637 cases and
18,083 controls of European ancestry. After quality con-
trol exclusions, ~1.3 million SNPs with minor allele fre-
quency (MAF) > 5% were meta-analyzed in the discovery
stage using an appropriate effect model selected according
to the heterogeneity test results. We conﬁrmed that the
two data sets came from populations with a common
distribution by generating the Manhattan and QQ plots
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(shown in Fig. 1 and Supplementary Fig. S1). The genomic
inﬂation factor (λGC) for the meta-analysis was then cal-
culated to be at 1.019. This GWAS meta-analysis yielded a
total of nine independent loci (deﬁned by at least 1Mb
separation between each other) reaching suggestive
genome-wide signiﬁcance (p< 1.0× 10–6, Supplementary
Table S2).
Those suggestive loci were then tested for their asso-
ciations with major mood disorders in two additional
samples (named Replication sample I as described above),
including 5754 cases and 5655 controls in total, and the
majority of the participants in Replication sample I were
from China (5303 cases and 5337 controls, Supplementary
Table S1). Notably, meta-analysis of populations with
diverse ethnic backgrounds may increase the power to
detect novel complex trait loci. This kind of study exhibits
greater resolution for the ﬁne-mapping of causal variants
via leveraging differences in local linkage disequilibrium
(LD) structure between ethnic groups44. Therefore, we
believe that such trans-ethnic replication (European and
Asian populations) will increase our conﬁdence with the
authenticity of the identiﬁed risk signal. Among the nine
independent suggestive loci implicated in the GWAS
meta-analysis, we found that three (2q11.2, 8q21.3, and
11q13.2) reached nominal signiﬁcance in the Replication
sample I (p< 0.05, Table 1 and S2). Meta-analysis in the
sample pool combining discovery GWAS data sets and
Replication sample I (including a total of 25,391 cases and
23,738 controls) showed that SNPs at 2q11.2, 8q21.3 and
11q13.2 were genome-wide signiﬁcantly associated with
major mood disorders (p< 5.0× 10–8, Table 1 and Sup-
plementary Table S2).
Although two SNPs in high LD (Europeans, r2= 0.97;
East Asians, r2= 0.99) at 11q13.2 showed genome-wide
signiﬁcant associations with mood disorders in the dis-
covery GWAS meta-analysis (rs7120256, p= 4.13× 10–8;
rs7119426, p= 4.33× 10–8; Fig. 1 and Supplementary
Table S2), they were not replicated in the Replication
sample I (rs7120256, p= 0.479; rs7119426, p= 0.415;
Supplementary Table S2). This phenomenon likely
resulted from the genetic heterogeneity of these loci
between populations. By contrast, there were other SNPs
at 11q13.2 showing suggestive genome-wide signiﬁcant
associations in the GWAS meta-analysis (e.g., rs10791889,
p= 4.40× 10–7; rs2167457, p= 6.92× 10–8; Table 1 and
Supplementary Table S2), and were also associated (or
marginally associated) with mood disorders in the Repli-
cation sample I (rs10791889, p= 0.012; rs2167457, p=
0.071; Table 1 and Supplementary Table S2). In the meta-
analysis combining GWAS data sets and Replication
sample I, we found that the latter two SNPs showed
genome-wide signiﬁcant associations (rs10791889, p=
1.70× 10–8; rs2167457, p= 1.69× 10–8; Table 1). A
detailed LD examination revealed that rs10791889 and
rs2167457 were in high LD (Europeans, r2= 0.92; Chi-
nese, r2= 0.80); both were in strong LD with rs7120256
and rs7119426 in Europeans (r2 ≥ 0.90), but in much
weaker LD in Chinese population (r2< 0.60)
Fig. 1 Manhattan plot of the meta-analyses BPD and MDD GWAS data sets. Horizontal line indicates threshold for genome-wide signiﬁcance (p
< 5 × 10−8)
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(Supplementary Fig. S2). These data provide likely
explanations for the divergent associations of the SNPs in
the Replication sample I.
Several SNPs at 2q11.2 and 8q21.3 also achieved
genome-wide signiﬁcance when pooling the GWAS data
sets and data of Replication sample I together (Supple-
mentary Table S2), with the same direction of allelic
effects in both European and Chinese populations. In
contrast, other suggestive genome-wide signiﬁcant SNPs
within genomic regions of 1p31.1, 3p21.1, 3q11.2, 4q22.3,
17p12, and 20q13.12 in GWAS meta-analysis of European
populations, were not signiﬁcant in the Replication sam-
ple I (Supplementary Table S2).
Validations in replication sample II and joint meta-analyses
We further examined the genome-wide signiﬁcant SNPs
at 2q11.2 (rs17022433 and rs717454), 8q21.3
(rs10103191) and 11q13.2 (rs10791889 and rs2167457) in
Replication sample II, which included a total of 6610 cases
and 70,978 controls worldwide. In this replicative analysis,
11q13.2 SNPs were suggestively associated with major
mood disorders (rs10791889, p= 1.48× 10–2; Table 1),
with the same direction of allelic effects as seen in the
discovery GWAS meta-analysis. Notably, rs10791889 is
the only SNP showing the genome-wide signiﬁcance in
the discovery and replication sample I, and was also
nominally replicated in the independent replication
sample II. The 2q11.2 and 8q21.3 SNPs, though not
reaching nominal signiﬁcance, showed the same trend of
association with the discovery analysis (Table 1). We then
combined samples from the GWAS datasets plus Repli-
cation sample I and II, which yielded a total of 32,001
cases and 94,716 controls, and conducted joint meta-
analyses in this pooled sample. We found that SNPs at
2q11.2 (rs717454), 8q21.3 (rs10103191) and 11q13.2
(rs10791889 and rs2167457) were genome-wide sig-
niﬁcantly associated with major mood disorders
(rs717454, p= 2.02× 10–8; rs10103191, p= 2.55× 10–8;
rs10791889, p= 9.36× 10–10; rs2167457, p= 4.92× 10–9;
Table 1). Regional plots of the risk loci are presented in
Fig. 2. SNPs in 2q11.2 and 8q21.3 were novel mood dis-
orders risk SNPs that have not been previously reported,
and SNPs at 11q13.2 were in high LD with potential BPD
risk SNPs implicated in previous GWAS analyses
(rs10896135 was reported in those GWAS with p-value of
1.56× 10–7, and it was in high LD with rs10791889 (r2>
0.9))20. The trans-ethnic replications increased our con-
ﬁdence with the authenticity of the risk loci, and were also
consistent with our in prior hypotheses that most of the
genome-wide signiﬁcant SNPs would exhibit similar
allelic frequencies between European and Asian popula-
tions (Europeans/Asians: rs717454-T, 0.570/0.688;
rs10791889-T, 0.267/0.151; rs2167457-T, 0.272/0.133; for
the only exception rs10103191, Europeans/Asians:
rs10103191-A, 0.481/0.867).
We then stratiﬁed the samples based on the case diag-
nostic status to examine the associations of the genome-
wide signiﬁcant variants with BPD (14,698 cases and
75,914 controls) or MDD (17,303 cases and 18,802 con-
trols) alone. This stratiﬁed analysis revealed that the SNPs
at 11q13.2 had larger effect sizes and stronger associations
with BPD than with MDD, while SNPs at 2q11.2 and
8q21.3 showed similar effect sizes between BPD and
MDD (Table 1). All the SNPs were associated with both
disorders at nominal signiﬁcance level.
Effects of the risk SNPs on nearby gene expression
The association between the risk SNPs with mood dis-
orders in multiple independent samples lends statistical
and biological support to the involvement of these
genomic regions in risk for these disorders. However,
these ﬁndings do not identify the underlying molecular
mechanisms. Accumulating lines of evidence suggest that
genetic risk factors likely contribute to the disease via
affecting the expression of certain genes45–48. To explore
whether transcriptional regulation explains the molecular
mechanism underlying the risk SNPs identiﬁed in our
Fig. 2 Regional plots of 2q11.2, 8q21.3, and 11q13.2 risk SNPs with major depressive disorder. 40A physical map of the region is given and
depicts known genes within the region, and the European population was used for the construction of LD structure
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meta-analyses, we carried out investigations using two
existing eQTL databases42,43.
In the GTEx expression database42, the 2q11.2 SNPs
(rs17022433 and rs717454) were signiﬁcantly and selec-
tively associated with LYG1 expression in the cerebellum
(rs17022433, p= 0.0039; rs717454, p= 0.017; Fig. 3).
More importantly, such associations in the cerebellum
were replicated in the Braineac43 (rs17022433, p= 0.011;
rs717454, p= 0.015; Supplementary Fig. S3). Rs10791889
and rs2167457 at 11q13.2 were signiﬁcantly and speciﬁ-
cally associated with the expression of C11orf80 in the
cerebellum in GTEx database (rs10791889, p= 0.00051;
rs2167457, p= 0.0017; Fig. 3). In Braineac, this associa-
tion was replicated with marginal statistical signiﬁcance in
the cerebellum with the same allelic direction
(rs10791889, p= 0.055; rs2167457, p= 0.079; Supple-
mentary Fig. S3). While LYG1 and C11orf80 were the only
signiﬁcant genes in respective genomic risk regions, the
eQTL associations survived multiple corrections and were
repeatedly observed across independent data sets.
Therefore, LYG1 and C11orf80 are likely reliable mood
disorder related genes, and may contribute to the cere-
bellum associated pathogenic processes in the disease
development. In fact, it has been reported that the cere-
bellum plays potential roles in psychiatric illnesses via its
participation in the cortico-ponto-cerebello-thalamo-
cortical circuit, by which it communicates with and
modulates various congitive domains of the cerebral
cortex; additionally, its role in motor coordination and
procedural skill learning has been well established49–51.
Konarski et al.50 have initially examined and synthesized
the evidence from functional association studies of cere-
bellar stimulation, lesions, and brain imaging, through
which they proposed the landmark hypothesis that
abnormalities of the cerebellum play a crucial role in
several psychiatric disorders including MDD and BPD.
Discussion
Major mood disorders are highly heritable traits, but the
genetic association (e.g., GWAS) discoveries so far
account for only a small portion of the inherited disease
risk, which is probably primarily due to the polygenic
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nature and/or highly heterogeneous genetic architecture
of the illnesses. However, GWAS remains an important
approach, and it is widely accepted that the accumulation
of such discoveries with growing sample sizes will serve as
important steps toward the elucidation of biological
pathways with etiologic relevance. As a result, mining the
current available genetic data sets will help to identify
previously undiscovered risk loci, deepening our knowl-
edge of the pathogenesis of major mood disorders and
providing valuable information about the genetic basis of
these illnesses52–55.
The current study is the ﬁrst report of genome-wide
signiﬁcant association between genetic variants on chro-
mosome 2q11.2 and 8q21.3 and major mood disorders,
although a limited number of previous studies have
detected suggestive evidence of association in these
regions15,20,31. We have also conﬁrmed the associations of
SNPs on chromosome 11 with mood disorders, which is
consistent with a previous BPD GWAS20. These lines of
evidence suggest potential involvement of those genomic
regions in the illnesses, and eQTL analyses in brains have
also highlighted certain genes. However, the functions of
those genes in brain development and mood disorders are
still unclear, so that further investigations are needed.
As previous major mood disorder GWAS have high-
lighted several genes, located elsewhere in the genome
confer the risk of these illnesses20,30,31,33, we also tested
those genes in our analyses. We detected nominal asso-
ciation for most of them (Supplementary Table S3), but
our results cannot be considered as independent replica-
tions, as the samples we used partially overlapped with
those in the previous studies20,30,31,33. A special mention
deserves the intergenic SNP rs9834970 (TRANK1/LBA1
gene) that was not signiﬁcant in the current meta-analysis
of GWAS data sets (Supplementary Table S3) but was
signiﬁcant in the separate analysis of the Romanian BPD-
type I sample41 and the Japanese BPD sample22 with the
same direction of the effect as in the discovery study33.
Notably, the signiﬁcant results in our study may be dif-
ferent from those of the previous genome-wide ana-
lyses20,30,31,33, but this is not unexpected since each study
has certain limitations in their power to detect the asso-
ciation and other unmeasurable factors such as sampling
or technical differences between different studies may also
contribute to this inconsistency. Therefore, even with
such a large cohort, the aforementioned limitations might
affect the power of this meta-analysis to capture all sig-
niﬁcant risk alleles at the genome-wide level.
Our genetic association results support the previous
hypothesis that BPD and MDD share common genetic risk
components12. However, these data are not sufﬁcient to
explain the phenomenon that only certain individuals
among the risk variants carriers will develop BPD or MDD,
while the others will remain healthy. Potential reasons may
include the limited knowledge of the genetic risk variants
for these illnesses, environmental inﬂuences, epistatic
effects between variants, and perhaps unknown epigenetic
factors.
This study also highlights the importance and necessity
of utilizing public resources to dissect the genetic basis of
complex diseases, such as major mood disorders. Many of
the published GWAS have released (or partially released)
their genome-wide statistical results18–20. Even though
those GWAS have identiﬁed a limited number of genome-
wide risk variants due to the sample size, they provided
valuable data sets for further analyses and we believe that
there are authentic undetected “treasures” underlying
these public resources. In this case, we performed a meta-
analysis of two public mood disorder GWAS data sets,
followed by a set of independent replications, in which
some of the replication samples were also available from
public sources. Intriguingly, we identiﬁed some novel loci
for major mood disorders with high conﬁdence, suggest-
ing that this approach is effective in studying major mood
disorders, and may also be applicable in investigating
other complex diseases.
Despite identifying several risk loci for major mood
disorders, this study also raises the concern of potential
bias of GWAS. Our current analyses largely rely on data
of cases deﬁned with wide diagnostic categories including
all possible clinical presentations, and the fact that dif-
ferent cohorts were assembled by different researchers
will thus introduce substantial variations regarding the
clinical spectrum of cases. For example, systematic var-
iation can occur in potentially important variables
including disease symptoms, functional impairment,
severity, comorbidity, response to interventions, familial
loading, relevant environmental exposures, etc. As a
result, the loci conferring risk across a broad phenotypic
spectrum are most likely to emerge56. Therefore, future
studies identifying the loci conferring risk of more speciﬁc
symptoms are needed57, which will require different
strategies for phenotypic reﬁnement and the use of mul-
tiple large and well-characterized samples. A good
example for this idea is the GWAS analyses of female
individuals with recurrent MDD to reduce phenotypic
heterogeneity, and successfully identiﬁed two genome-
wide risk loci in a moderate sample size21. Besides, there
are caveats remain to be addressed in the current study.
For example, although we identiﬁed novel risk loci for
major mood disorders, the lack of experimental investi-
gation prevents us from further understanding their bio-
logical roles in the pathogenesis of the illnesses. Future
studies on how these SNPs and genes confer risk of mood
disorders are thus necessary.
In summary, using public resources, our GWAS meta-
analysis followed by independent replications has identi-
ﬁed several risk loci for categorically deﬁned BPD and
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MDD. This is a clear demonstration of the genetic overlap
between the major mood disorders that may explain
susceptibility to such illnesses and conditions. These
results not only contribute to our understanding of the
pathogenesis of major mood illnesses, but also provide
essential help in future reformation of psychiatric nosol-
ogy, by contributing to a future scheme reﬂecting the
underlying biology of psychiatric conditions rather than
relying solely on the current diagnostic and classiﬁcation
system.
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